Chengdu Aorui Pharmaceutical

Chengdu Origen Biotechnology is a clinical-stage biopharmaceutical company headquartered in Chengdu, China, and is a key R&D subsidiary of the publicly traded Aoruite Pharmaceutical. The company specializes in the development of next-generation small molecule targeted therapies for cancer, with a focus on addressing resistance mechanisms in precision oncology. Its lead candidate, ORI-C11, is a potent and selective inhibitor of EGFR and HER2 exon 20 insertions, currently in Phase 1/2 clinical trials for non-small cell lung cancer. Origen Biotech also advances ORI-C101, a KRAS G12C inhibitor, and other programs targeting ALK and ROS1. The company leverages a structure-based drug design platform and has received investment from prominent firms like Qiming Venture Partners. Origen Biotech aims to deliver innovative treatment options for cancer patients by tackling undruggable targets.